来曲唑对比阿那曲唑辅助治疗绝经后激素受体阳性淋巴结阳性早期乳腺癌的疗效与安全性比较:FACE随机III期试验最终结果
FACE研究将4136例绝经后激素受体阳性、淋巴结阳性早期乳腺癌患者随机分配至来曲唑(2.5 mg)或阿那曲唑(1 mg)每日一次辅助治疗5年。最终分析时709例无病生存事件,来曲唑组5年无病生存率84.9%对比阿那曲唑组82.9%(HR 0.93,95%CI 0.80-1.07,P=0.3150),总生存率89.9%对比89.2%(HR 0.98,95%CI 0.82-1.17,P=0.7916)。来曲唑对比阿那曲唑未显示出显著优效的疗效或安全性。
要点
- 来曲唑组5年无病生存率84.9%对比阿那曲唑组82.9%,差异未达统计学显著(HR 0.93,95%CI 0.80-1.07,P=0.3150)。
- 来曲唑组5年总生存率89.9%对比阿那曲唑组89.2%,差异未达统计学显著(HR 0.98,95%CI 0.82-1.17,P=0.7916)。
- 两组3-4级不良事件(>5%患者)包括关节痛(来曲唑3.9%对比阿那曲唑3.3%)等,总体安全性相似。
核心结论
- 在绝经后激素受体阳性、淋巴结阳性早期乳腺癌患者中,来曲唑对比阿那曲唑未显示出显著优效的疗效或安全性。
研究设计与样本
- FACE研究为随机III期临床试验,纳入绝经后激素受体阳性、淋巴结阳性早期乳腺癌患者。
- 患者随机接受来曲唑(2.5 mg)或阿那曲唑(1 mg)每日一次辅助治疗5年或直至疾病复发。
- 按淋巴结数量和人类表皮生长因子受体2状态进行分层,主要终点为5年无病生存率,关键次要终点为总生存率和安全性。
- 共4136例患者随机分配至来曲唑组(n=2061)或阿那曲唑组(n=2075)。
主要发现
- 最终分析时共709例无病生存事件:来曲唑组341例(16.5%),阿那曲唑组368例(17.7%)。
- 来曲唑组5年估计无病生存率为84.9%,阿那曲唑组为82.9%(HR 0.93,95%CI 0.80-1.07,P=0.3150)。
- 探索性分析显示来曲唑与阿那曲唑在所有评估亚组中无病生存率相似。
- 来曲唑组5年估计总生存率为89.9%,阿那曲唑组为89.2%(HR 0.98,95%CI 0.82-1.17,P=0.7916)。
- 来曲唑对比阿那曲唑最常见的3-4级不良事件(>5%患者)包括关节痛(3.9%对比3.3%,所有不良事件48.2%对比47.9%)、高血压(1.2%对比1.0%)、潮热(0.8%对比0.4%)、肌痛(0.8%对比0.7%)、呼吸困难(0.8%对比0.5%)和抑郁(0.8%对比0.6%)。
临床怎么用
- 来曲唑对比阿那曲唑在绝经后激素受体阳性、淋巴结阳性早期乳腺癌辅助治疗中未显示出显著优效的疗效或安全性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC). Methods Postmenopausal women with HR-positive and node-positive eBC were randomly assigned to receive adjuvant therapy with either letrozole (2.5 mg) or anastrozole (1 mg) once per day for 5 years or until recurrence of disease. Patients were stratified on the basis of the number of lymph nodes and human epidermal growth factor receptor 2 status. The primary end point was 5-year disease-free survival (DFS), and the key secondary end points were overall survival and safety. Results A total of 4,136 patients were randomly assigned to receive either letrozole (n = 2,061) or anastrozole (n = 2,075). The final analysis was done at 709 DFS events (letrozole, 341 [16.5%]; anastrozole, 368 [17.7%]). The 5-year estimated DFS rate was 84.9% for letrozole versus 82.9% for anastrozole arm (hazard ratio, 0.93; 95% CI, 0.80 to 1.07; P = .3150). Exploratory analysis showed similar DFS with letrozole and anastrozole in all evaluated subgroups. The 5-year estimated overall survival rate was 89.9% for letrozole versus 89.2% for anastrozole arm (hazard ratio, 0.98; 95% CI, 0.82 to 1.17; P = .7916). Most common grade 3 to 4 adverse events (> 5% of patients) reported for letrozole versus anastrozole were arthralgia (3.9% v 3.3%, and 48.2% v 47.9% for all adverse events), hypertension (1.2% v 1.0%), hot flushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depression (0.8% v 0.6%). Conclusion Letrozole did not demonstrate significantly superior efficacy or safety compared with anastrozole in postmenopausal patients with HR-positive, node-positive eBC.
引用
- Smith I, Yardley D, Burris H, et al. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. J Clin Oncol. 2017. PMID: 28113032. doi:10.1200/JCO.2016.69.2871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。